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Abstract
©  2016  Springer  Science+Business  Media  DordrechtObjective:  Myelin  oligodendrocyte
glycoprotein  (MOG)  is  one  of  the  major  autoantigens  in  multiple  sclerosis  (MS),  therefore
selective depletion of autoreactive lymphocytes exposing MOG-specific B cell receptors (BCRs)
would be beneficial in terms of MS treatment. Results: Using E. coli we generated an efficient
protocol  for  the  purification  of  the  recombinant  immunotoxin  DT-MOG  composed  of  the
extracellular Ig-like domain of MOG fused in frame with the catalytic and translocation subunits
of diphtheria toxin (DT, Corynebacterium diphtheriae) under native conditions with a final yield
of 1.5 mg per liter of culture medium. Recombinant DT-MOG was recognized in vitro by MOG-
reactive  antibodies  and  has  catalytic  activity  comparable  with  wild-type  DT.  Conclusion:
Enhanced pharmacokinetics (mean residence time in the bloodstream of 61 min) and minimized
diminished nonspecific  toxicity  (LD50 = 1.76 mg/kg)  of  the  DT-MOG makes it  a  potential
candidate for the immunotherapy of MS.
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